Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2017; 71(1): 40–48. doi:10.14735/amgh201740.

Skin conditions in patients with inflammatory bowel diseases

Kateřina Jůzlová1, Martina Krásová1, Jana Herzogová1

+ Affiliation

Summary

Inflammatory bowel diseases (IBD) may also manifest on the skin. Skin manifestation can occur in 22–44% of patients with Crohn’s disease (CD) and it is the most common extraintestinal manifestation of CD. Specific lesions, reactive lesions, and associated diseases are among the skin manifestations of CD. Specific lesions have the same histopathological findings as CD. Erythema nodosum, pyoderma gangrenosum, and aphthous stomatitis are among the reactive lesions of CD and each presents a different histopathological picture. Psoriasis, atopic dermatitis, and hidradenitis suppurativa are also diseases associated with CD. Peristomal dermatitis and dermatosis due to malabsorption and malnutrition are another issue in CD patients. Dermatosis caused by IBD treatment is another important problem in patients with IBD. Skin side-effects can occur in 20% patients undergoing biological treatment. The most common dermatosis in these patients is atopic dermatitis, paradoxical reactions, and bacterial skin diseases, such as pyoderma. A paradoxical reaction is defined as the induction or exacerbation of a disease by a drug (s) approved for the disease. In the case of skin manifestations, it is not always necessary to withdraw the prescribed drug. Given the relatively high occurrence of diverse skin reactions in patients suffering from IBD, close cooperation between gastroenterologists and dermatologists is highly recommended.

Keywords

atopic dermatitis, inflammatory bowel disease, infection, skin manifestations, skin neoplasms, psoriasis

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Fialová J, Vojáčková N, Stránská J et al. Kožní projevy Crohnovy choroby. Čes Dermatoven 2012; 2 (3): 168–172.
2. Bonheur JL, Braunstein J, Korelitz BI et al. Anal skin tags in inflammatory bowel disease: new observations and a clinical review. Inflamm Bowel Dis 2008; 14 (9): 1236–1239. doi: 10.1002/ibd.20 458.
3. Thrash B, Patel M, Shah KR et al. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol 2013; 68 (2): 211.e1–211.e33. doi: 10.1016/j.jaad.2012.10.036.
4. Jůzlová K, Votrubová J, Fialová J et al. Kožní projevy gastrointestinálních chorob. Postgrad Med 2013; 15 (3): 34–37.
5. Jůzlová K, Hercogová J. Kůže – zrcadlo vnitřních nemocí. Vnitř Lék 2016; 62 (7–8): 575–581.
6. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. 2nd ed. New York: Mosby 2008.
7. Cetkovská P, Pizinger K, Štork J. Kožní změny u interních onemocnění. 1. vyd. Praha: Grada Publishing 2010: 51–59.
8. Braun-Falco O, Plewig G, Wolff HH et al. Dermatology. 2nd ed. Berlin, Heidelberg, New York: Springer 2000: 912–915.
9. Slezák K, Dřízhal I. Atlas onemocnění ústní sliznice. Praha: Quintessenz 2004: 190–192.
10. Hercogová J. Psoriasis. Čes Dermatoven 2011; 1 (1): 8–26.
11. Votrubova J, Juzlova K, Smerhovsky Z et al. Risk factors for comorbidities in Czech psoriatic patients: results of a hospital-based case-control study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014; 158 (2): 288–294.
12. Jůzlová K, Votrubová J, Krásová M et al. Rizikové faktory komorbidit psoriázy využitelné v sekundární prevenci. Čes Dermatoven 2016; 6 (2): 7–23.
13. Darsow U, Raap U, Ständer S. Atopic dermatitis. In: Carstens E, Akiyama T (eds). Itch: mechanisms and treatment. Boca Raton (FL): CRC Press 2014.
14. Yazdanyar S, Miller IM, Jemec GB.  Hidradenitis suppurativa and Crohn’s disease: two cases that support an association. Acta Dermatovenerol Alp Pannonica Adriat 2010; 19 (3): 23–25.
15. Van der Zee HH, van der Woude CJ, Florencia EF et al. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 2010; 162 (1): 195–197. doi: 10.1111/j.1365-2133.2009.09430.x.
16. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab of inflammatory bowel disease: a single centre cohort study. Gut 2009; 58 (4): 501–508. doi: 10.1136/gut.2008.163642.
17. Fréling E, Baumann C, Cuny JF et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol 2015; 110 (8): 1186–1196. doi: 10.1038/ajg.2015.205.
18. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009; 20 (2): 100–108. doi: 10.1080/0954663 0802441234.
19. Collamer AN, Guerrero KT, Henning JS et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59 (7): 996–1001. doi: 10.1002/art.23835.
20. Cullen G, Kroshinsky D, Cheifetz AS et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34 (11–12): 1318–1327. doi: 10.1111/j.1365-2036.2011.04866.x.
21. de Gannes GC, Ghoreishi M, Pope J et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143 (2): 223–231.
22. Tillack C, Ehmann LM, Friedrich M et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63 (4): 567–577. doi: 10.1136/gutjnl-2012-302853.
23. Sansó Sureda A, Rocamora Durán V, Sapiña Camaró A et al. Ustekinumab in a patient with Crohn’s disease and anti-TNF-α-induced psoriasis. Gastroenterol Hepatol 2011; 34 (8): 546–550. doi: 10.1016/j.gastrohep.2011.04.003.
24. Michaëlsson G, Kajermo U, Michaëlsson A et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005; 153 (6): 1243–1244.
25. Pugliese D, Guidi L, Ferraro PM et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther 2015; 42 (7): 880–888. doi: 10.1111/apt.13352.
26. Wollina U, Hansel G, Koch A et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9 (1): 1–14. Erratum in: Am J Clin Dermatol 2008; 9 (5):  347.
27. Medkour F, Babai S, Chanteloup E et al. Development of diffuse psoriasis with alopecia during treatment of Crohn’s disease with infliximab. Gastroenterol Clin Biol 2010; 34 (2): 140–141. doi: 10.1016/j.gcb.2009.10.021.
28. Bremmer M, Deng A, Gaspari AA. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: part 2. Dermatitis 2009; 20 (5): 243–256.
29. Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 2004; 3 (3): 315–318.
30. Džambová M, Sečníková Z, Rob F et al. Spinocelulární karcinom. Čes Dermatoven 2015; 5 (1): 7–18.
31. Mackintosh LJ, Geddes CC, Herd RM. Skin tumours in the West of Scotland renal transplant population. Br J Dermatol 2013; 168 (5): 1047–1053. doi: 10.1111/bjd.12129.
32. Bernat García J, Morales Suárez-Varela M, Vilata JJ et al. Risk factors for non-melanoma skin cancer in kidney transplant patients in a Spanish population in the Mediterranean region. Acta Derm Venereol 2013; 93 (4): 422–427. doi: 10.2340/000 15555-1525.
33. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65 (2): 253–261. doi: 10.1016/j.jaad.2010.11.062.
34. Sečníková Z, Džambová M, Vojáčková N et al. Kožní nemoci u pacientů po transplantaci. Čes Dermatovener 2012; 2 (4): 244–249.
35. Sečníková Z, Džambová M, Hercogová J. Role virů, UV záření a imunosuprese v patogenezi kožních nádorů u pacientů po transplantaci orgánů. Čes Dermatovener 2014; 4 (2): 88–93.
36. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2: CD008794. doi: 10.1002/14651858.CD008794.pub2.
37. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn’s disease: Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012; 107 (9): 1409–1422. doi: 10.1038/ajg.2012.218.
38. Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013; 108 (12): 1835–1842. doi: 10.1038/ajg.2013.294.

 

Print

Credited self-teaching test

Start test

Most Read (last 6 month)

  1. Colorectal cancer screening in the Czech Republic
  2. Pancreatic cancer surveillance in high-risk individuals Position statement of professional societies
  3. Trends in premature mortality from digestive system cancers in Slovakia in the years 2011–2020: 8 diagnoses over 10 years
  4. Results from the evaluation of colorectal cancer screening in the Czech Republic
  5. Mixed adenoneuroendocrine carcinoma of the stomach – a case report
  6. Subcutaneous infliximab in the treatment of refractory Crohn‘s disease patients – a pilot study of drug immunogenicity
  7. Urolithiasis in patients with inflammatory bowel disease – possibilities of prevention and metabolic influence
  8. Subcutaneous infliximab – treatments and new possibilities after clinical practice